-
Something wrong with this record ?
Brief Story on Prostaglandins, Inhibitors of their Synthesis, Hematopoiesis, and Acute Radiation Syndrome
M. Hofer, Z. Hoferová, M. Falk,
Language English Country Switzerland
Document type Journal Article, Review
Grant support
19-09212S
Grantová Agentura České Republiky
NLK
Directory of Open Access Journals
from 1997
Free Medical Journals
from 1997
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 1997-01-01
Open Access Digital Library
from 1997-01-01
Medline Complete (EBSCOhost)
from 2009-03-01
Health & Medicine (ProQuest)
from 1997-01-01
- MeSH
- Acute Radiation Syndrome blood drug therapy etiology metabolism MeSH
- Cyclooxygenase 1 metabolism MeSH
- Cyclooxygenase 2 metabolism MeSH
- Hematopoiesis drug effects MeSH
- Cyclooxygenase 2 Inhibitors pharmacology therapeutic use MeSH
- Humans MeSH
- Metabolic Networks and Pathways drug effects MeSH
- Disease Models, Animal MeSH
- Prostaglandins biosynthesis pharmacology MeSH
- Radiation-Protective Agents pharmacology therapeutic use MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Prostaglandins and inhibitors of their synthesis (cyclooxygenase (COX) inhibitors, non-steroidal anti-inflammatory drugs) were shown to play a significant role in the regulation of hematopoiesis. Partly due to their hematopoiesis-modulating effects, both prostaglandins and COX inhibitors were reported to act positively in radiation-exposed mammalian organisms at various pre- and post-irradiation therapeutical settings. Experimental efforts were targeted at finding pharmacological procedures leading to optimization of therapeutical outcomes by minimizing undesirable side effects of the treatments. Progress in these efforts was obtained after discovery of selective inhibitors of inducible selective cyclooxygenase-2 (COX-2) inhibitors. Recent studies have been able to suggest the possibility to find combined therapeutical approaches utilizing joint administration of prostaglandins and inhibitors of their synthesis at optimized timing and dosing of the drugs which could be incorporated into the therapy of patients with acute radiation syndrome.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005720
- 003
- CZ-PrNML
- 005
- 20200518132037.0
- 007
- ta
- 008
- 200511s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/molecules24224019 $2 doi
- 035 __
- $a (PubMed)31698831
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Hofer, Michal $u Department of Cell Biology and Radiobiology, Institute of Biophysics, v.v.i., Czech Academy of Sciences, Královopolská 135, 61265 Brno, Czech Republic.
- 245 10
- $a Brief Story on Prostaglandins, Inhibitors of their Synthesis, Hematopoiesis, and Acute Radiation Syndrome / $c M. Hofer, Z. Hoferová, M. Falk,
- 520 9_
- $a Prostaglandins and inhibitors of their synthesis (cyclooxygenase (COX) inhibitors, non-steroidal anti-inflammatory drugs) were shown to play a significant role in the regulation of hematopoiesis. Partly due to their hematopoiesis-modulating effects, both prostaglandins and COX inhibitors were reported to act positively in radiation-exposed mammalian organisms at various pre- and post-irradiation therapeutical settings. Experimental efforts were targeted at finding pharmacological procedures leading to optimization of therapeutical outcomes by minimizing undesirable side effects of the treatments. Progress in these efforts was obtained after discovery of selective inhibitors of inducible selective cyclooxygenase-2 (COX-2) inhibitors. Recent studies have been able to suggest the possibility to find combined therapeutical approaches utilizing joint administration of prostaglandins and inhibitors of their synthesis at optimized timing and dosing of the drugs which could be incorporated into the therapy of patients with acute radiation syndrome.
- 650 _2
- $a akutní radiační syndrom $x krev $x farmakoterapie $x etiologie $x metabolismus $7 D054508
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a cyklooxygenasa 1 $x metabolismus $7 D051545
- 650 _2
- $a cyklooxygenasa 2 $x metabolismus $7 D051546
- 650 _2
- $a inhibitory cyklooxygenasy 2 $x farmakologie $x terapeutické užití $7 D052246
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a hematopoéza $x účinky léků $7 D006410
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a metabolické sítě a dráhy $x účinky léků $7 D053858
- 650 _2
- $a prostaglandiny $x biosyntéza $x farmakologie $7 D011453
- 650 _2
- $a radioprotektivní látky $x farmakologie $x terapeutické užití $7 D011837
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Hoferová, Zuzana $u Department of Cell Biology and Radiobiology, Institute of Biophysics, v.v.i., Czech Academy of Sciences, Královopolská 135, 61265 Brno, Czech Republic.
- 700 1_
- $a Falk, Martin $u Department of Cell Biology and Radiobiology, Institute of Biophysics, v.v.i., Czech Academy of Sciences, Královopolská 135, 61265 Brno, Czech Republic.
- 773 0_
- $w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 24, č. 22 (2019)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31698831 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200518132037 $b ABA008
- 999 __
- $a ok $b bmc $g 1524578 $s 1095776
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 24 $c 22 $e 20191106 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- GRA __
- $a 19-09212S $p Grantová Agentura České Republiky
- LZP __
- $a Pubmed-20200511